Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

visual field testing

  • Home
  • visual field testing
Evaluating the Clinical Utility of 10-2 Visual Field Testing in Early Glaucoma Progression Detection
Posted innews Ophthalmology

Evaluating the Clinical Utility of 10-2 Visual Field Testing in Early Glaucoma Progression Detection

Posted by MedXY By MedXY 07/09/2026
This study assesses the added value of 10-2 visual field testing compared to the 24-2 test in detecting progression of early glaucoma, highlighting its role in patients with localized central visual field loss.
Read More
  • Decoding Resistance to Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm: The Role of TXNRD1 and TET2 Mutations
  • Unveiling Non-PF4/Heparin-Binding, Platelet-Activating Antibodies in Heparin-Induced Thrombocytopenia: Implications for Diagnosis and Pathogenesis
  • Radiation Exposure in Bronchoscopy: Conventional Fluoroscopy versus Robotic Techniques
  • Enhancing Treatment Evaluation in Fibrotic Interstitial Lung Disease: A Joint Model of Lung Function Decline and Mortality
  • Evaluating the ISOLD Score for Accurate Diagnosis of Vitreoretinal Lymphoma in Clinical Practice
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in